Talis Biomedical Corporation (TLIS) |
|
0.54 0.014 (2.6%)
|
03-22 15:18 |
|
Open: |
0.55 |
Pre. Close: |
0.5263 |
|
High:
|
0.55 |
Low:
|
0.53 |
|
Volume:
|
15,858 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:51:29 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.69 One year: 0.74 |
| Support: |
Support1: 0.51 Support2: 0.43 |
| Resistance: |
Resistance1: 0.59 Resistance2: 0.63 |
| Pivot: |
0.56  |
| Moving Average: |
MA(5): 0.53 MA(20): 0.56
MA(100): 0.56 MA(250): 0.78 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.9 %D(3): 8 |
| RSI: |
RSI(14): 42.2 |
| 52-week: |
High: 1.58 Low: 0.42 |
| Average Vol(K): |
3-Month: 116 (K) 10-Days: 59 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TLIS ] has closed above bottom band by 26.8%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.54 - 0.54 |
0.54 - 0.55 |
|
Low:
|
0.51 - 0.52 |
0.52 - 0.52 |
|
Close:
|
0.52 - 0.53 |
0.53 - 0.53 |
|
Company Description |
|
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. |
Headline News |
Tue, 21 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com
Thu, 03 Nov 2022
Talis Biomedical Reports Third Quarter 2022 Financial Results - GlobeNewswire
Tue, 16 Aug 2022
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate - Simply Wall St
Thu, 17 Mar 2022
Talis Biomedical Aims For Manufacturing Turnaround (NASDAQ:TLIS) - Seeking Alpha
Thu, 10 Feb 2022
TLIS LAWSUIT ALERT: Levi & Korsinsky Notifies Talis Biomedical Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - WTVG
Sat, 08 Jan 2022
TALIS BIOMEDICAL SHAREHOLDER ALERT BY FORMER ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
0 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
1.418e+007 (%) |
|
% Held by Institutions
|
10.1 (%) |
|
Shares Short
|
235 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0934e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
134.6 |
|
Return on Equity (ttm)
|
-29.1 |
|
Qtrly Rev. Growth
|
5.41e+006 |
|
Gross Profit (p.s.)
|
232.54 |
|
Sales Per Share
|
-48.96 |
|
EBITDA (p.s.)
|
-1.31053e+008 |
|
Qtrly Earnings Growth
|
-13.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-127 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
234790 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
